-+ 0.00%
-+ 0.00%
-+ 0.00%

Eikon Therapeutics Gets FDA Clearance for EIK1006 Prostate Cancer Trial

PUBT·11/17/2026 11:03:19
Listen to the news
Eikon Therapeutics Gets FDA Clearance for EIK1006 Prostate Cancer Trial
  • Eikon Therapeutics received FDA clearance to begin a first-in-human Phase 1/2 trial of EIK1006 for advanced metastatic prostate cancer.
  • Dosing is expected to begin in 2027, with preliminary safety and efficacy data due in the second half of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eikon Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611170600PRIMZONEFULLFEED9879204) on November 17, 2026, and is solely responsible for the information contained therein.